Deerfield Management Company, L.P. (Series C) Mersana Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 15, 2024	BUY	$2.16 - $5.94 $124,152 - $341,419	57,478 New	57,478 $257,000
Q2 2023 Aug 14, 2023	BUY	$3.08 - $9.55 $8.89 Million - $27.6 Million	2,885,400 New	2,885,400 $9.49 Million

Others Institutions Holding MRSN

# of Institutions

125

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

Eco R1 Capital, LLC San Francisco, CA

19.4M
Shares

$11.8 Million
1.59% of portfolio
Nextech Invest Ag

12.1M
Shares

$7.36 Million
3.72% of portfolio
Vr Adviser, LLC New York, NY

11.3M
Shares

$6.91 Million
2.22% of portfolio
Bain Capital Life Sciences Investors, LLC Boston, MA

8.66M
Shares

$5.28 Million
2.94% of portfolio
Black Rock Inc. New York, NY

8.38M
Shares

$5.11 Million
0.0% of portfolio

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $59.3M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account